Agitation Associated with Alzheimer’s Disease research hub

CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)

This study looks at a new drug, KarXT, for people with Alzheimer's disease who experience agitation. It's an extension of previous studies, checking the long-term safety and how well people tolerate the medication. Researchers want to see if it causes any unwanted side effects over time.